Sanofi to Begin at Least 10 Phase 3 Studies Over Next 12 Months
13 December 2017 - 08:09PM
Dow Jones News
By Anthony Shevlin
France's Sanofi SA (SAN.FR) said Wednesday that it expects to
begin at least ten phase 3 studies over the next 12 months,
following a preview of its research-and-development strategy and
pipeline for 2018.
The pharmaceutical company said that the studies will include
evaluations of new treatments for chronic obstructive pulmonary
disease and eosinophilic esophagitis, for autosomal dominant
polycystic kidney disease and for type 2 diabetes.
Sanofi said that in the next 12 months its regulatory filings
are set to include two investigational cancer drugs--cemiplimab and
isatuximab--a novel therapy for type 1 diabetes called
sotagliflozin and a potential treatment for uncontrolled,
persistent asthma called dupilumab.
In total, the company's pipeline includes 71
research-and-development projects, 37 of which are new molecular
entities and novel vaccines.
Sanofi will host an analysts meeting later Wednesday to discuss
its development pipeline and milestones for 2018 further.
Write to Anthony Shevlin at anthony.shevlin@dowjones.com
(END) Dow Jones Newswires
December 13, 2017 03:54 ET (08:54 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Feb 2024 to Mar 2024
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Mar 2023 to Mar 2024